Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses

An anti-respiratory and Eucheuma technology, applied in the field of medicine, can solve problems such as impact and complex anti-coagulation effects, and achieve high promotional value, low toxicity, and strong anti-respiratory virus activity.

Active Publication Date: 2015-06-24
GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its anticoagulant effect is extremely complex and affects many aspects of the coagulation process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses
  • Application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses
  • Application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1, Determination of Molecular Weight Range of Eucheuma Polysaccharide

[0024] a. Precisely weigh 1mg of Eucheuma polysaccharide, dissolve it in 0.2M sodium acetate buffer solution with a pH value of 4.0 to a final concentration of 1mg / ml, and filter it through a 0.45um microporous membrane for use.

[0025] b. Dextran Mw800T, 505T, 170T, 60T. Accurately weigh 0.100 g of dextran standard substances with different molecular weights, dissolve them in mobile phase and dilute to 10 mL, and the final concentration is 10 mg / mL.

[0026] c. The standard product and Eucheuma polysaccharide samples were detected by high performance liquid phase, the mobile phase was 0.2M sodium acetate buffer solution with a pH value of 4.0, the chromatographic conditions were flow rate 1.0mL / min, injection volume 10μl, injection time 15min . The coordinate curve was drawn with the separation retention time (RT) of different molecular weight standard dextran and the corresponding ...

Embodiment 2

[0028] Embodiment 2, Study on Cytotoxicity of Polysaccharides from Eucheuma agaricus

[0029] 1. Test material

[0030] The extracted Eucheuma polysaccharide was prepared into a 10 mg / mL aqueous solution with pure water, and stored at -20°C for later use.

[0031] 2. Test method

[0032] Dilute Eucheuma agaricus polysaccharides to different concentrations (initial concentration is 500μg / mL), and observe under an inverted microscope to observe the maximum non-toxic concentration of the drug TC 0 , Determination of cytotoxicity of Eucheuma polysaccharides.

[0033] 3. Test results

[0034] The highest non-toxic concentration TC0 for each strain of cells is taken as the highest drug dilution concentration that does not cause cell death in normal cells and does not cause cytopathic changes. LEGP) components were not toxic to MDCK, HeLa, Hep-2 cells at the concentrations used in the experiments.

[0035] Table 1 Cytotoxicity of CEGP and LEGP

[0036]

Embodiment 3

[0037] Embodiment 3, Anti-respiratory tract-associated virus efficacy experiment of Eucheuma qiongzhi polysaccharides

[0038] a. Polysaccharides were extracted from Eucheuma agaricus, with an average molecular weight of 45,000 and a monosaccharide sulfate group substitution degree of 2.13.

[0039] b. Referring to the results of the cytotoxicity experiment in Example 2, the Eucheuma agaricus polysaccharide extracted in step a was prepared into a dilution with an initial concentration of 62.5 μg / mL, and the anti-respiratory tract-associated virus activity was determined by the MTT method.

[0040] c. Step: Inoculate cells in 96-well culture plates with a cell density of 1.5*10 5 pcs / ml, 100μl per well, 37℃, 5%CO 2 Cultivate in the incubator for 16-20 h, wait until it grows into a single layer of cells, discard the culture medium, wash with PBS three times, and mix different dilutions of drugs (within the non-toxic concentration range) and virus dilution (100TCID 50 ) each 50...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicines and particularly relates to application of eucheuma gelatinae polysaccharide to preparation of medicines for inhibiting respiratory viruses. The average molecular mass of the eucheuma gelatinae polysaccharide ranges from 1,000 to 100,000. Pharmacological experiments show that the eucheuma gelatinae polysaccharide has the function of independently inhibiting respiratory viruses which mainly include respiratory syncytial viruses, Coxsackie viruses and influenza viruses. The inventor uses ribavirin together with eucheuma gelatinae polysaccharide and heparin together with eucheuma gelatinae polysaccharide to inhibit respiratory viruses, and results shown that ribavirin and eucheuma gelatinae polysaccharide or heparin and eucheuma gelatinae polysaccharide can be used together to achieve an unexpected treatment effect synergistically. Antiviral medicines such as tablets, capsules, granules, sustained-release tablets and sprays can be prepared from eucheuma gelatinae polysaccharide. The eucheuma gelatinae polysaccharide has strong respiratory virus inhibiting activity, has low toxicity on a host cell, can be used for preparing medicines with high antiviral activity and low toxicity and has broad application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the use of Eucheuma agaricus polysaccharide in preparing anti-respiratory virus drugs. Background technique [0002] Respiratory viruses are a class of viruses that can invade the respiratory tract or use the respiratory tract as the entry point to cause lesions in the respiratory tract and tissues and organs outside the respiratory tract. Respiratory viruses include influenza viruses in the family Orthomyxoviridae; parainfluenza viruses in the family Paramyxoviridae, respiratory syncytial virus, measles virus, mumps virus, and some viruses in other virus families such as adenoviridae Viruses, rubella virus, rhinovirus, coronavirus and reovirus, etc. According to statistics, more than 90% of acute respiratory infections are caused by viruses. The common respiratory viruses are H1N1 influenza virus, H3N2 influenza virus, H5N3 influenza virus, respiratory syncytial v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/737A61P31/12A61P31/16
Inventor 王一飞邹沐平董栋夏敏廖晓凤刘秋英
Owner GUANGZHOU JINAN BIOMEDICINE RES & DEV CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com